- Investors & Media
- Investors & Media
- Contact Us
NESS ZIONA, Israel (March 5, 2014) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation a Phase 2/3 clinical trial…
NESS ZIONA, Israel (March 4, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its…
NESS ZIONA, Israel (February 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening…
Total revenue for the fourth quarter of 2013 increased 13% to $24.4 million from $21.6 million for the fourth quarter of 2012, reflecting higher revenue in the Proprietary Products Segment. Total revenue increased 40% compared with the third quarter of 2013.
Fourth quarter proprietary products revenues posted a record high of $18.6 million
Expects top-line data from European Phase 2/3 trial of inhaled AAT for AATD in 1Q and
initiation of two important clinical trials in coming weeks
Conference call begins today at 8:30 a.m. Eastern time
Kamada management will host an investment community conference call on Wednesday, February 5, 2014 beginning at 8:30 a.m. Eastern time
The multicenter randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of Kamada's inhaled formulation of human AAT to treat AATD in >160 patients.
Kamada expects to report top-line results from this study in the first quarter of 2014.
Expects to Report Top-Line Results in First Quarter 2014; Preparations Underway for European Regulatory Filing in Second Half of 2014
Experienced Executive to Expand Opportunities for the Company's Protein Therapeutics Platform
New results in T1D pediatric patients indicate 60% of patients still maintain active pancreatic beta cells that secrete self-insulin approximately 10 months after last Glassia treatment
Large percentage of patients have very good glycemic control; Phase II/III trial to initiate by end of 2013